Skip to content
Research Article Open access CC BY 4.0

Convalescent Plasma for COVID-19- is it Time to Say Goodbye? A Single-Center, Retrospective, Observational Study from Northern India

Rasika Setia, Mitu Dogra, Gokhula Prasath Thangavel, Ramesh Yadav, Amena Ebadur Rahman, Atul Bhasin, Rajesh Kumar Pande, Sandeep Nayar, R. K. Singal, Anil Vardani, Deepak Gargi Pande, R. N. Saini, Tribhuvan GulatI, Vivek Pal Singh, Sunny Kalra, Gagan Anand, Manish Garg, Santosh Ghai, N. M. Agarwal

International Blood Research & Reviews · pp. 32–43 · Published 7 Sep 2021

10.9734/ibrr/2021/v12i430158

Abstract

Background: COVID-19 pandemic continues threatening the world with no effective treatment to tackle the menace. Till date, there is conflicting evidence on efficacy of CP in reducing COVID-19 related mortality. The objective of this study was to see disease progression and 7, 14 and 28-day mortality after CP therapy and analyze CP efficacy with/without Remdesivir. Materials and Methods: A retrospective single-centre observational study done from August 20, 2020, to 20 November 2020. Records of 294 COVID-19 patients with moderate to severe disease given CP therapy were analysed based on disease progression and length of hospital stay, further subcategorized on age, clinical profile, risk factors, ward/ICU, ventilatory support and co-administration of Remdesivir. Results: Lowest 7-day mortality rate was seen within age group 20-40 years (0%) and was highest in ≥61 years (24.3%). 87 patients on ventilatory support showed higher 28day mortality (48.28%) compared to non-ventilated (10.14%), (P<0.00001). Lesser 7-day mortality was seen in early CP therapy ≤3 days of admission (P=0.01). Patients requiring ICU admission showed higher 14 and 28-day mortality compared to ward P=0.001%). Median (IQR) length of hospital stay from CP transfusion was shorter, 4 (3 to 9) days in group 2 (CP only) compared to 7 (4 to 12) days in group1 (CP+Remdesivir ). Conclusion: CP therapy in ≤3 days of hospital admission in COVID-19 patients with moderate to severe infection not on ventilatory support showed reduction in mortality and length of hospital stay. Length of hospital stay was shorter in the CP-only group as compared to the CP+ Remdesivir group.

convalescent plasma COVID-19 ARDS CP therapy

References (28)

  1. 1 Home visits: a strategy to improve newborn survival - Authors' reply [DOI]
  2. 2 Convalescent plasma as a potential therapy for COVID-19 [DOI]
  3. 3 A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia [DOI]
  4. 4 Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults [DOI]
  5. 5 Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) [DOI]
  6. 6 The immune system [DOI]
  7. 7 Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19 [DOI]
  8. 8 Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial [DOI]
  9. 9 Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study [DOI]
  10. 10 Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma [DOI]
  11. 11 Pathogenesis of COVID-19-induced ARDS: implications for an ageing population [DOI]
  12. 12 Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study [DOI]
  13. 13 The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis [DOI]
  14. 14 Use of convalescent plasma in hospitalized patients with COVID-19: case series [DOI]
  15. 15 The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.
  16. 16 The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report [DOI]
  17. 17 Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell–Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19) [DOI]
  18. 18 Early mortality benefit with COVID‐19 convalescent plasma: a matched control study [DOI]
  19. 19 Effectiveness of convalescent plasma in Indian patients with COVID-19 [DOI]
  20. 20 Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients – propensity-score matched case-control study [DOI]
  21. 21 Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study [DOI]
  22. 22 COVID‐19 convalescent plasma therapy: hit fast, hit hard! [DOI]
  23. 23 Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) [DOI]
  24. 24 Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report [DOI]
  25. 25 Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia [DOI]
  26. 26 Combination of convalescent plasma therapy and repurposed drugs to treat severe COVID‐19 patient with multimorbidity [DOI]
  27. 27 Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience [DOI]
  28. 28 Convalescent Plasma for COVID-19. A randomized clinical trial [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

35

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.